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Introduction
Multiple myeloma (MM) is a disorder of clonal cells that aggregate in the bone marrow
(BM) stromal compartment. The MM cells are characterized by immune dysfunction, deregulated cell signaling, and high secretion of monoclonal protein detectable
in the blood and/or urine.1,2 MM primarily affects older individuals with a mean age
of diagnosis between 63 years and 70 years of age.3 The disease constitutes 1.5% of
all cancers and almost 15% of all hematological malignancies. There are ∼86,000
new cases of MM occurring worldwide each year, with MM accounting for an estimated 11,090 deaths in the US in 2014 and an estimated 10,390 deaths in Europe in
2012.4 The introduction of the novel agents, including proteasome inhibitors (PIs)
(bortezomib – Velcade and carfilzomib – Kyprolis) and immunomodulatory drugs
(thalidomide – Thalomid, lenalidomide – Revlimid, and pomalidomide – Pomalyst),
was an important advance in the therapy of MM.5,6 The combination regimens of
these drugs and autologous stem cell transplantation substantially extended the average MM patient survival.3 Bortezomib was the first PI approved by the US Food and
Drug Administration (FDA) in 2003 for relapsed/refractory MM patients, and also a
few years later for treating newly diagnosed MM patients.7
Despite revolutionizing the treatment of MM, there are several limitations for the
bortezomib treatment, including 1) not every MM patient will respond to bortezomib
as a first-line therapy; 2) the majority of patients who initially respond favorably to
bortezomib may later develop drug resistance and relapse; 3) peripheral neuropathy (PN) is a dose-limiting toxicity of bortezomib, which can potentially result in
permanent nerve damage to the extremities;8 and 4) other common side effects of bortezomib include fatigue, gastrointestinal effects, and modest cytopenias.8 Bortezomib
is administered intravenously (iv) and recently subcutaneously (sc), which showed
similar bioavailability with noninferior efficacy and a significantly lower incidence of
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Abstract: Despite the significant therapeutic advances achieved with proteasome inhibitors
(PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple
myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic
limitations continue to pose major challenges when using these compounds. Ixazomib is a
second-generation PI with improved activity over other PIs. Unlike bortezomib and carfilzomib,
which are administered by injection, ixazomib is the first oral PI approved by US Food and
Drug Administration. This review discusses the biochemical properties, mechanisms of action,
preclinical efficacy, and clinical trial results leading to the US Food and Drug Administration
approval of ixazomib.
Keywords: proteasome inhibitor, oral administration, biological mechanism, clinical trials
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PN compared to iv administration.9–12 Moreover, the safety
profile of bortezomib was further improved by reducing
dosing frequency from twice weekly to once weekly.13 A
second-generation PI, carfilzomib, was approved by the US
FDA in 2012 for the treatment of MM patients. Carfilzomib
offered a therapeutic benefit to a fraction of patients who
relapsed from bortezomib treatment while showing decreased
PN.14 Nonetheless, drug resistance was also observed following carfilzomib treatment.15 One likely contributor to this
resistance is the drug efflux pump P-glycoprotein (P-gp).
Carfilzomib is a known P-gp substrate, and a few studies
have demonstrated that carfilzomib-resistant cells exhibited
increased P-gp expression.16–18 A significant limitation of the
treatment with bortezomib and carfilzomib is that both these
drugs are administered iv, which implies the need for health
care professionals to administer the dose in a clinic or a hospital, which inevitably reduces the patient’s quality of life and
increases the treatment costs.19 Ixazomib (Ninlaro) is a small
molecule PI that overcomes the aforementioned limitations
of bortezomib and carfilzomib. In November 2015, ixazomib
became the first orally administered PI to be approved by the
US FDA. In this review, we highlight the chemical properties,
biological activity, and mechanism of action of ixazomib,
as well as summarize the clinical trials to test its efficacy in
patients with MM.

Chemical structure and mechanism
of action of ixazomib
Ixazomib (formerly known as MLN9708) was developed
through a large-scale screening of boron-containing PIs
with physiochemical properties distinct from bortezomib, in
pursuit of efficacious PIs with increased efficacy and reduced
side effects.20–22
Bortezomib structurally resembles dipeptide
phenylalanine–leucine in which the terminal carboxylic acid
is replaced by boric acid (Table 1).23 Bortezomib is a slowly
reversible inhibitor of the β1 caspase-like subunit and β2
trypsin-like subunit, with preference to the β5 chymotrypsinlike subunit of 20S proteolytic site of proteasome.21,24
Inhibition of the catalytic β5 site occurs when the boric acid
group forms covalent bound with the hydroxyl group of the
N-terminal threonine residue.22,25 On the other hand, carfilzomib has a tripeptide backbone containing phenylalanine,
leucine, and homophenylalanine with terminal epoxyketone
group (Table 1).23,26 Carfilzomib is an irreversible inhibitor
with high specificity for the β5 chymotrypsin-like subunit
of the proteasome.27 Ixazomib belongs to the same structural
class and acts through the same mechanism as bortezomib.
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Ixazomib consists of an alanine–leucine dipeptide core with
a citrate-protected boric acid and preferentially inhibits the
β5 chymotrypsin-like subunit of proteasome, which cleaves
proteins after hydrophobic residues. Furthermore, at high
concentrations, ixazomib is capable of inhibiting other proteolytic sites of 20S proteasome, including the β1 caspase-like
subunit, which cleaves proteins after acidic residues, and
β2 trypsin-like subunit, which cleaves after basic residues
(Table 1 and Figure 1).22
Ixazomib is a citrate ester of boronic acid, which when
exposed to aqueous solutions (eg, gastrointestinal tract and
plasma) hydrolyzes to free boric acid metabolite MLN2238
that carries the biological effect (Figure 1).21 Xenograft
mouse models demonstrated that ixazomib has significantly
higher antitumor activity, which is attributed to distribution
of larger blood volume compared to bortezomib, conferring
greater pharmacodynamics.21,22 The clinical trials of ixazomib
showed low incidence of PN compared to bortezomib, which
may be ascribed to the high specificity of ixazomib in inhibiting the chymotrypsin-like site of the 20S proteasome.21,28
Moreover, ixazomib elicits therapeutic response in patients
who were bortezomib resistant.14,20

Biological mechanisms of ixazomib
Cell signaling pathways
In vitro studies performed with different human MM cell
lines treated with various concentrations of ixazomib showed
a concentration-dependent decrease in the viability of all
treated cell lines. Furthermore, it was shown that ixazomib
induced apoptosis of MM cell lines resistant to conventional
therapies and in primary MM cells obtained from bortezomiband lenalidomide-resistant patients.20 The apoptotic activity
of ixazomib was mediated by the activation of caspase-8,
caspase-9, and caspase-3 and other apoptotic pathways such
as p53–p21, p53–NOXA–PUMA, and Rb–E2F. Ixazomib
also induced the expression of binding immunoglobulin
protein and CCAAT-enhancer-binding protein homologous
protein transcription factor – both connected to endoplasmic
reticulum stress response.20
MicroRNA profiling studies with MM cells showed that
ixazomib induced upregulation of miR33b, a tumor suppressor gene that is constitutively expressed at low levels in
MM cells. Increased miR33b expression leads to cell death
and apoptosis by blocking proto-oncogene (PIM-1) via
inhibiting serine/threonine kinase activity. Furthermore, this
increased expression is associated with reduced migration
and viability of MM cells, as well as increased sensitivity
to ixazomib.29
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Figure 1 Mechanism of action of ixazomib.
Notes: Ixazomib (MLN9708) administered orally as a capsule is rapidly absorbed and hydrolyzed to the biologically active form (MLN2238) when it comes in contact with
aqueous plasma. Ixazomib blocks protein degradation by inhibiting the 20S catalytic subunit of the 26S proteasome. More specifically, at lower concentrations, MLN2238
inhibits the β5 chymotrypsin-like subunit, which cleaves proteins after hydrophobic residues. At high concentrations, MLN2238 inhibits the β1 caspase-like subunit and
β2 trypsin-like subunit, which cleave proteins after acidic and basic residues, respectively.

Antitumor activity of ixazomib in vivo
Treatment of MM-bearing mice with ixazomib induced a
significant inhibition of MM tumor growth and a significant
increase in survival compared to vehicle- and bortezomibtreated mice. In accordance with the in vitro data, when compared to vehicle-treated mice, ixazomib-treated mice showed
an increase in the number of cleaved caspase-3-positive
cells, increase in the number of TUNEL-positive cells, and
decrease in the proliferation marker Ki-67. Immunostaining
of harvested mouse tumors revealed that ixazomib inhibited
the angiogenic activity of tumors and reduced the expression of angiogenesis markers such as vascular endothelial
growth factor receptor 2 and platelet endothelial cell adhesion molecule, while displaying normal levels of creatinine,
hemoglobin, and bilirubin.20
220
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Anti-BM microenvironment activity of
ixazomib
Acellular components include cytokines and growth factors,
which facilitate cell proliferation, extracellular matrix, a
scaffold promoting cell-cell interactions, and hypoxia niche,
which causes limited oxygen diffusion as well as alters
gene expression promoting drug resistance.30,31 Cellular
components include stromal cells, which facilitate adhesion
and proliferation,32–35 endothelial cells, which create blood
vessels thus contribute to metastasis, 36 and osteoblasts/
osteoclasts, which contribute to bone lytic lesions. 37,38
In vitro, ixazomib inhibited the NF-κB pathway in MM
stromal cells, reducing the release of cytokines that are
vital for growth and survival of MM cells. Thus, treatment
with ixazomib disrupts the cytoprotective effects of the BM
Drug Design, Development and Therapy 2016:10
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microenvironment on MM cells and inhibits proliferation
of MM cells.20
Osteolytic lesions are the most common complication of
MM.39 It was demonstrated that ixazomib has a positive effect
against MM-induced bone lytic lesions, since it inhibited
osteoclast resorption with efficiency similar to bortezomib.
It was demonstrated that early osteoclast differentiation
was mediated by multiple signaling pathways that involve
NF-κB; ixazomib decreased NF-κB signaling in preosteoclasts by impairing the degradation of the cellular NF-κB
inhibitor, I-κB, by inhibiting the proteasome, which consequently reduced osteoclastogenesis.39 Moreover, in terms
of osteoblast activity, ixazomib enhanced differentiation of
osteoblast from primary mesenchymal stem cells isolated
from myeloma and enhanced osteoblast functions.39

Pharmacokinetic and pharmacodynamic
parameters in animal models
Biochemical analysis showed that the potency and selectivity of ixazomib and bortezomib to β1, β2, and β5 subunits
of proteasome are of the same magnitude, with preferential
inhibitory activity towards β5 subunit with the half maximal
inhibitory concentration (IC50) for ixazomib 3.4 nmol/L and
for bortezomib 2.4 nmol/L. The half-life (t1/2) of dissociation
of ixazomib from the proteasome was found to be approximately six times shorter than that of bortezomib (18 minutes
versus 110 minutes), which was consistent with the recovery
of proteasome activity with bortezomib-treated cells recovering slower than ixazomib-treated cells.22
However, when administered iv, ixazomib was shown
to have superior pharmacokinetic parameters compared
with bortezomib; the maximal plasma concentration (Cmax)
of ixazomib was 17,000 ng/mL compared to 321 ng/mL for
bortezomib. In addition, ixazomib provided a greater plasma
exposure (area under the curve [AUC0–24 h] =8,090 h⋅ng/mL)
compared with bortezomib (AUC0–24 h =485 h⋅ng/mL), when
both PIs were injected iv using their maximum tolerated
doses. Moreover, ixazomib demonstrated five times higher
drug distribution from blood into tissues supported by blood
volume distribution, Vd, of 20.2 L/kg compared to Vd =4.3 L/kg
for bortezomib.

Ixazomib in clinical trials
Phase I clinical trial
Study design

Being the first oral PI, the clinical trials of ixazomib in
patients with relapsed and/or refractory MM began with openlabel, Phase I dose-escalation studies and expansion cohort
studies.19 In these studies, ixazomib was given twice weekly
Drug Design, Development and Therapy 2016:10
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(0.24–2.23 mg/m2 on days 1, 4, 8, and 11 of a 21-day cycle) to
60 patients who met the following criteria: .18 years old with
a measurable disease, an absolute neutrophil count $1,000
cells/mm3, platelet count $75,000 cells/mm3, a total bilirubin
#1.5× the upper limit of normal, aspartate aminotransferase
and alkaline aminotransferase #2.5× upper limit of normal,
and creatinine clearance $20 mL/min within 3 days of receiving the first dose. The exclusion criteria included uncontrolled
preexisting comorbidities that may interfere with the study,
as well as the previous treatment with a PI. Dose escalation
of ixazomib was done in a standard 3+3 scheme with the
modified Fibonacci dose sequence. Investigators analyzed the
dose-limiting toxicities that occurred in patients during cycle
1 in order to determine the maximum tolerated dose.19

Toxicity and adverse effects
Of the patients who remained on the maximum tolerated dose
of 2.0 mg/m2, or an equivalent fixed dose of 3.7 mg, ∼62%
experienced drug-related grade $3 adverse events (AEs),
27% of whom were grade 4. The most common drug-related
AEs included nausea (42%), thrombocytopenia (42%),
fatigue (40%), skin and subcutaneous tissue disorders (40%),
vomiting (25%), diarrhea (23%), pyrexia (20%), neutropenia
(18%), PN (12%), and chills (10%). Of the seven patients
with drug-related PN, three patients experienced grade 1 PN
at baseline, while others experienced a worsening of PN to
grade 2 in cycle 2 at 0.8 mg/m2 in the cohort study, worsening from baseline while remaining at grade 1 in cycle 2 at
1.68 mg/m2 in the cohort study, or worsening grade 2 during
cycle 3 of the relapsed and refractory cohort.
In the dose-escalation cohort with 2.0 mg/m2 ixazomib
given twice weekly, a patient experienced spinal cord compression as a result of disease progression during cycle 1.
In the relapsed and refractory cohort studies, five people
discontinued treatment due to drug-related thrombocytopenia
during cycle 1, drug-related nausea and fatigue with PN during cycle 5, and pneumonia in cycle 2 as well as cycle 5. Two
dose-limiting toxicities of grade 3 rash and grade 4 thrombocytopenia occurred with 2.23 mg/m2 of ixazomib.19

Pharmacokinetics and pharmacodynamics in Phase I
clinical trials
Ixazomib displayed rapid absorption with a maximal concentration time (Tmax) of 1 hour, Cmax of 7.78 ng/mL, and a terminal t1/2 of 3.3–7.4 days following a dose of 0.48 mg/m2. Linear
pharmacokinetics was observed with a direct proportionality
between the plasma concentration (7.78–75.9 ng/mL) and the
administered dose (range of 0.48–2.23 mg/m2). The Phase
I study showed that 2.0 mg/m2 of ixazomib administered
submit your manuscript | www.dovepress.com
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orally twice weekly was the optimal dose for efficacy and
AEs. This dose elicited a positive response and was effective
in controlling the disease, while the AEs were reversible,
minor, and manageable.19

Phase II clinical trials
Study design

Open-label Phase II trials were initiated to test the safety,
tolerability, and efficacy of ixazomib.7 Phase II trials also
investigated the efficacy of the addition of dexamethasone
to the ixazomib therapy. Patients were required to be at least
18 years, have relapsed MM after one or more attempted therapies, have a measurable disease (serum M-protein $1 g/dL
or urine M-protein $200 mg/24 hours or involved free
light chain level $10 mg/dL), have an Eastern Cooperative Oncology Group performance status of 0–2, absolute
neutrophil count $1,000 cells/mm3, platelets $75,000 cells/
mm3, and could not be on a CYP1A2 or CYP3A4 inducer/
inhibitor within 14 days of study. The patients were also
excluded from the study, if they experienced any of the following disease states: uncontrolled cardiovascular conditions
(hypertension, cardiac arrhythmias, congestive heart failure,
unstable angina, or myocardial infarction within the past
6 months), HIV, positive hepatitis B surface antigen, hepatitis C infection, or patient allergy to any of the medications,
analogs of the medications, or excipients that may interfere
with the bioavailability of the drug. In total, 33 patients with
relapsed MM were enrolled in this trial, and on average, the
patients had previously received two alternative therapies.
The treatment goal was to receive an overall response rate
of the drug using only a single agent in relapsed MM with
no prior use of a PI or less than six cycles of therapy with
a previous PI. The secondary goal was to obtain an overall
response rate of the drug with the addition of dexamethasone.
Patients in the Phase II study received, on average, eight
cycles of therapy: 19 patients received four cycles, 16 patients
received eight cycles, and the remaining 12 patients received
12 cycles. The median dose that 27 patients received per cycle
was 12 mg of ixazomib, ranging from 5.5 mg to 15.6 mg. Dexamethasone was administered at the following occasions: 1)
at the end of cycle 2, 2) when patients showed no response to
ixazomib alone by the end of cycle 4, or 3) if the patient experienced disease progression at any point during the treatment.7

Toxicity and adverse effects
AEs experienced by patients in the Phase II trial were
identical to those experienced in the Phase I studies – 40%
experienced grade 3 or grade 4 and 19% experienced grade 4.
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Common AEs included thrombocytopenia, fatigue, nausea,
and diarrhea. No patients died during the study period.
Drug-induced grade 1 and grade 2 PN was observed in eight
patients and five patients, respectively. No hematological
toxicity was recorded; however, three patients discontinued
drug therapy due to elevated stringent complete response
(sCR) and thrombotic thrombocytopenic purpura.7

Efficacy
As a single agent, ixazomib is therapeutically effective in
treating patients with relapsed and refractory MM, with
minimal rates of PN. Overall, the Phase II studies showed
that 34% of patients experienced partial response or better
during the entire trial without the addition of dexamethasone. Two additional patients experienced a minor response,
and one patient had both CR and sCR. In all, 67% of the
patients were initiated on dual dexamethasone treatment,
out of which, 17 patients were placed on the secondary
therapy for not achieving a response with ixazomib alone
and five patients were placed on the secondary therapy for
progression of the disease. Those treated with the secondary
therapy achieved a response rate of 34% after the dexamethasone addition. Of the patients in cycle 4, five patients
experienced a positive response to treatment, three patients
experienced a partial response to treatment, one patient
achieved a complete response to therapy, and one patient
achieved an sCR.7
A number of Phase II clinical trials are evaluating a
three-drug regimen (or more) including ixazomib, lenalidomide, and dexamethasone for four cycles, followed by
a randomized maintenance therapy with either ixazomib
or lenalidomide in order to prolong the disease-free period
in patients after stem cell transplantation (NCT02253316).
Other randomized Phase I/II trials are testing a combination
of ixazomib with or without pomalidomide and dexamethasone given together in treating patients with refractory MM
(NCT02004275). In addition, ixazomib is being evaluated
in previously untreated symptomatic myeloma patients
with high risk of progression, where patients are treated in
combination with cyclophosphamide and dexamethasone
(NCT01864018; Table 2).

Phase III clinical trial
There are a number of ongoing Phase III clinical trials examining the efficacy of ixazomib on progression-free survival,
overall survival, and overall response rate at different
stages of MM. These trials are randomized, double blinded,
multicenter, and placebo controlled. No results have been
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Phase

Identifier

Post-ASCT
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Post-ASCT
Relapsed
Post-ASCT
Plasma cell leukemia
Relapsed/refractory
Relapsed/refractory
Relapsed/refractory

Relapsed/refractory
Newly diagnosed
Newly diagnosed
Relapsed/refractory
Residual disease after SCT
High risk post-ASCT

Relapsed/refractory
Newly diagnosed
Relapsed/refractory
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Newly diagnosed
Newly diagnosed
Relapsed/refractory
Relapsed/refractory

Light chain amyloidosis
Relapsed/refractory
Relapsed high risk

Relapsed/refractory
Relapsed/refractory
Relapsed/refractory

Stage of MM

Table 2 Summary of completed and ongoing clinical trials of ixazomib in MM

Ixazomib, lenalidomide, dexamethasone,
placebo
Ixazomib, placebo

Ixazomib
Ixazomib
Ixazomib, melphalan, methotrexate,
carmustine, cytarabine, etoposide, tacrolimus
Ixazomib, lenalidomide, dexamethasone
Ixazomib, melphalan, prednisone
Ixazomib, lenalidomide, dexamethasone
Ixazomib, pomalidomide, dexamethasone
Ixazomib, clarithromycin, pomalidomide,
dexamethasone
Ixazomib, dexamethasone, pomalidomide
Ixazomib, dexamethasone, cyclophosphamide
Ixazomib, melphalan, prednisone, lenalidomide,
cyclophosphamide, dexamethasone
Ixazomib, dexamethasone, bendamustine
Ixazomib, lenalidomide, dexamethasone
Ixazomib, cyclophosphamide, dexamethasone
Ixazomib
Ixazomib, lenalidomide, dexamethasone
Ixazomib, fludarabine, melphalan, bortezomib,
placebo
Ixazomib, cyclophosphamide, dexamethasone
Ixazomib
Ixazomib, dexamethasone, pomalidomide
Ixazomib, lenalidomide
Ixazomib, dexamethasone, pomalidomide
Ixazomib, cyclophosphamide, dexamethasone
Ixazomib, thalidomide, dexamethasone
Ixazomib, lenalidomide, dexamethasone,
placebo

Ixazomib
Ixazomib
Ixazomib

Intervention

No results provided

(Continued)

No results provided
No results provided
No results provided
No results provided
No results provided
No results provided
No results provided
Patients on ixazomib treatment as background therapy
to lenalidomide and dexamethasone experienced longer
progression-free survival compared to placebo group
No results provided

No results provided
No results provided
No results provided
No results provided
No results provided
No results provided

No results provided
No results provided
No results provided

No results provided
No results provided
No results provided
No results provided
No results provided

Clinical efficacy in pretreated MM patients
Safety and tolerability support once-weekly dosing
4.0 mg recommended dose, no dose-limiting toxicities
were reported
No results provided
No results provided
No results provided
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published yet. TOURMALINE-MM1 trial is being conducted
in 837 relapsed/refractory MM patients (NCT01564537) and
TOURMALINE-MM2 study in .700 newly diagnosed MM
patients (NCT01850524). In these two studies, one patient
group receives oral ixazomib (4 mg) and the other group
receives a placebo, while both groups receive lenalidomide
and dexamethasone. Moreover, ixazomib (3 mg) as a single
agent, compared to placebo, is being tested as a maintenance
therapy in patients following autologous stem cell transplantation (TOURMALINE-MM3; NCT02181413) and in
patients who have not received autologous stem cell transplantation (TOURMALINE-MM4; NCT02312258). A list
of completed and ongoing clinical trials involving ixazomib
in MM is given in Table 2.

No results provided
Plasma-cytoma
Not yet open
III

Conclusion

Abbreviations: MM, multiple myeloma; SCT, stem cell transplantation; ASCT, autologous stem cell transplantation.

No results provided
Relapsed/refractory

NCT02312258
TOURMALINE-MM4
NCT01659658
TOURMALINE-MM5
NCT02516423

III

Recruiting

Ixazomib, dexamethasone, melphalan,
cyclophosphamide, thalidomide, lenalidomide
Ixazomib, dexamethasone, lenalidomide,
zoledronic acid

No results provided
Ixazomib, placebo
Newly diagnosed
Recruiting

224

III

Stage of MM
Identifier

Table 2 (Continued)

Phase

Status

Intervention
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Ixazomib is the first oral boronic acid-based PI approved by
US FDA in combination with lenalidomide and dexamethasone for the treatment of MM patients who have received at
least one prior therapy. Preclinical results demonstrated that
ixazomib inhibits the chymotrypsin-like proteolytic (β5) site
of the 20S proteasome, reduces tumor progression by increasing MM cell apoptosis, and disrupts the interaction of MM
cells with the BM microenvironment resulting in decreased
angiogenesis and osteolytic lesions.
Currently, there are numerous clinical trials including
five global Phase III trials on investigational oral ixazomib
in MM and in other hematological malignancies such as
lymphoma and amyloidosis, as well as in solid tumors. Based
on study reports, ixazomib is therapeutically efficacious as
a single agent but especially when used in combination with
dexamethasone in the treatment of relapsed/refractory MM.
Side effects are manageable and infrequent, including rash,
lowered platelet and white blood cell counts, fatigue, diarrhea
and nausea, and with a few instances of PN. By virtue of the
convenience of oral administration, ixazomib is a promising
option for MM treatment and is being continuously evaluated
as a single agent or in combination with other therapies in
Phase III trials for relapsed/refractory patients, newly diagnosed patients, and as a maintenance therapy.
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